Top

BMC Neurology

Published in:

Open Access 01-12-2017 | Research article

Stability and relative validity of the Neuromuscular Disease Impact Profile (NMDIP)

Authors: Isaäc Bos, Jan B.M. Kuks, Josué Almansa, Hubertus P.H. Kremer, Klaske Wynia

Published in: BMC Neurology | Issue 1/2017

Abstract

Background

The aim of this study was to examine the stability and relative validity (RV) of the Neuromuscular Disease Impact Profile (NMDIP) using criterion-related groups. In a previous study the NMDIP-scales showed good internal consistency, convergent and discriminant validity. Known-groups analysis showed that the NMDIP discriminates between categories of extent of limitations.

Methods

A cross-sectional postal survey study was performed on patients diagnosed with a NMD and registered at the Department of Neurology, University Medical Center Groningen, the Netherlands.

Participants were asked to complete the preliminary NMDIP, the Medical Outcome study Short Form Questionnaire (SF-36), the World Health Organization Quality Of Life-abbreviation version (WHOQOL-bref), and two generic domain specific measures: the Groningen Activity Restriction Scale (GARS) and the Impact on Participation and Autonomy Questionnaire (IPAQ). The variables ‘Extent of Limitations’ and ‘Quality of Life’ were used to create criterion-related groups. Stability over time was tested using the Wilcoxon Signed Rank Test for paired samples and the intraclass correlation coefficients for repeated measures. RV was examined by comparing the ability of NMDIP with generic multidimensional health impact measures, and domain specific measures in discriminating between criterion-related subgroups using the Kruskal-Wallis H-test.

Results

Response rate was 70% (n = 702). The NMDIP-scales showed sufficient stability over time, and satisfactory or strong RV. In general, the NMDIP scales performed as well as or better than the concurrent measurement instruments.

Conclusions

The NMDIP proved to be a valid and reliable disease-targeted measure with a broad scope on physical, psychological and social functioning.

Marchettini P, Lacerenza M, Mauri E, Marangoni C. Painful peripheral neuropathies. Curr Neuropharmacol. 2006;4(3):175–81.CrossRefPubMedPubMedCentral

Bos I, Stallinga HA, Middel B, Kuks JBM, Wynia K. Validation of the ICF core set for neuromuscular diseases. Eur J Phys Rehabil Med. 2013;49(2):179–87.

Barry M, Edgman-Levitan S. Shared decision making—the pinnacle of patient-centered care. N Engl J Med. 2012;366:780–1.CrossRefPubMed

Bos I, Kuks J, Wynia K. Development and testing psychometric properties of an ICF-based health measure: The Neuromuscular Disease Impact Profile. J Rehabil Med. 2015;47(5):445–53.

Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical outcomes study. Med Care. 1995;33(4 Suppl):AS264–79.PubMed

Fayers PM, Machin D. Developing and testing questionnaires. In: quality of life: assessment, analysis and interpretation. Chichester: John Miley & Sons; 2000. doi:10.1002/9780470024522.

Rowland LP, McLeod JG. Classification of neuromuscular disorders. J Neurol Sci. 1994;124(Suppl(0022–510)):109–30.PubMed

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(0025-7079; 0025-7079;6):473–83.

The WHOQOL Group. Development of the World Health Organization WHOQOL-bref quality of life assessment. World Health Forum. 1998;28:551–8.

10.

Kempen GI, Miedema I, Ormel J, Molenaar W. The assessment of disability with the Groningen activity Restriction scale. Conceptual framework and psychometric properties. Soc Sci Med. 1996;43(0277–9536; 0277–9536; 11):1601–10.CrossRefPubMed

11.

Cardol M, de Haan RJ, de Jong BA, van den Bos GA, de Groot IJ. Psychometric properties of the impact on participation and autonomy questionnaire. Arch Phys Med Rehabil. 2001;82(0003–9993; 0003–9993; 2):210–6.CrossRefPubMed

12.

Graham C, Rose M, Grunfeld E, Kyle S, Weinman J. A systematic review of quality of life in adults with muscle disease. J Neurol. 2011;258(9):1581–92.CrossRefPubMed

13.

Burns TM, Graham CD, Rose MR, Simmons Z. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve. 2012;46(1):9–25.CrossRefPubMed

14.

Pavan K, Marangoni BEM, Zinezzi M, Schmidt K, Oliveira B, Buainain R, Lianza S. Validation of the amyotrophic lateral Sclerosis assessment questionnaire (ALSAQ-40) scale in the Portuguese language. Arq Neuropsiquiatr. 2010;68(1):48–51.CrossRefPubMed

15.

Wynia K, Middel B, van Dijk JP, De Ruiter H, De Keyser J, Reijneveld SA. The Multiple Sclerosis impact profile (MSIP). Development and testing psychometric properties of an ICF-based health measure. Disabil Rehabil. 2008;30(4):261–74.CrossRefPubMed

16.

Cardol M, de Haan RJ, van den Bos GA, de Jong BA, de Groot IJ. The development of a handicap assessment questionnaire: the impact on participation and autonomy (IPA). Clin Rehabil. 1999;13(0269–2155; 0269–2155; 5):411–9.CrossRefPubMed

17.

Streiner D, Norman G. Health measurement scales, a practical guide to their development and use. Fourth edition ed. Oxford: Oxford University Press; 2008.CrossRef

18.

McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66.CrossRefPubMed

19.

Wynia K, Middel B, De Ruiter H, van Dijk JP, De Keyser JHA, Reijneveld SA. Stability and relative validity of the Multiple Sclerosis impact profile (MSIP). Disabil Rehabil. 2008;30(14):1027–38.CrossRefPubMed

20.

Andersen M, Johnson U, Lindwall M, Ivarsson A. To adjust or not adjust: nonparametric effect sizes, confidence intervals, and real-world meaning. Psychol Sport Exerc. 2013;14(1):97–102.CrossRef

21.

Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.

Title: Stability and relative validity of the Neuromuscular Disease Impact Profile (NMDIP)
Authors: Isaäc Bos
Jan B.M. Kuks
Josué Almansa
Hubertus P.H. Kremer
Klaske Wynia
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2017
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-017-0866-6

At a glance: The STEP trials

Springer Medicine

Stability and relative validity of the Neuromuscular Disease Impact Profile (NMDIP)

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

To be active through indoor-climbing: an exploratory feasibility study in a group of children with cerebral palsy and typically developing children

Anterior sacral meningocele infected with Fusobacterium in a patient with recently diagnosed colorectal carcinoma – a case report

Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study

Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review

The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study

Post-operative re-bleeding in patients with hypertensive ICH is closely associated with the CT blend sign